Indivior price target raised to $36 from $28 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Indivior (INDV) to $36 from $28 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.